![](https://investorshub.advfn.com/uicon/69437.png?cb=1592321837)
Friday, June 26, 2009 1:19:14 PM
Even in cold weather, automobiles may overheat when exposed to direct sunlight. Excessive solar heat gain through clear or tinted glass results in occupant discomfort, excessive energy usage for cooling, and interior fading due to ultraviolet exposure.
XIR® is a transparent film that is encapsulated between layers of PVB (polyvinyl butyral) in laminated automotive glass to form a protective barrier against the harmful effects of the sun. Unlike other approaches that simply absorb and re-radiate heat, XIR film’s spectrally-selective metallic coating actually reflects destructive infrared and UV rays without impairing visible light transmission. XIR laminated glass reduces solar heat gain an average of 35% more effectively than tinted glass, increasing occupant comfort, improving fuel efficiency, and reducing interior fading.
See Clearly and Stay Cool
XIR film is virtually transparent, so it does not affect driver vision. XIR film also protects expensive upholstery and audio equipment by shielding it from over 94% of the sun’s destructive heat and 99% of harmful ultraviolet rays.
Improve Fuel Efficiency
XIR film helps to lower interior temperatures quickly, cooling the passenger cabin to minimize strain on the air conditioner and improve fuel efficiency. A July 2000 desert test program with the U.S Department of Energy’s National Renewable Energy Laboratory (NREL) reported that a test vehicle equipped with XIR reflective film technology had significantly reduced interior cabin temperatures and improved fuel economy by 3%.
Benefits
High light transmission – Virtually transparent
Improves occupant comfort – Blocks 94% of infrared radiation
Increases fuel efficiency – Cooler cabin decreases air conditioner loading
Protects skin and reduces interior fading – Blocks 99% of UV rays
Reduces external noise
Applications
Windshields
Side Lights
Sunroofs
Recent SWTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 10:36:23 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 10:34:23 AM
- SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 08/07/2024 10:30:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:01:45 PM
- SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors • GlobeNewswire Inc. • 07/29/2024 10:30:11 AM
- SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 • GlobeNewswire Inc. • 07/23/2024 11:00:02 AM
- Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm • PR Newswire (US) • 07/02/2024 04:49:00 PM
- SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN • GlobeNewswire Inc. • 07/01/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:15:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:07:38 PM
- SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/05/2024 11:00:52 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:37:20 PM
- SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:13:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:53:56 PM
- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference • GlobeNewswire Inc. • 05/08/2024 11:00:27 AM
- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates • GlobeNewswire Inc. • 05/02/2024 10:30:00 AM
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/24/2024 05:31:32 PM
- SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 • GlobeNewswire Inc. • 04/18/2024 11:00:28 AM
- SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN • GlobeNewswire Inc. • 03/04/2024 11:30:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:16:11 PM
- SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors • GlobeNewswire Inc. • 02/29/2024 01:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:28:17 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/27/2024 01:23:12 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2024 12:29:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 11:51:44 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM